Diabetic Retinopathy

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%

Fenofibrate added to simvastatin reduced progression of diabetic retinopathy by 36.3% (p=0.006) compared with simvastatin alone, measured by combined progression on funduscopic examination and need fo

Effect: improvement; -36.3%